Capital News

Sialorrhea Market is Projected to Boost at a Moderate Growth Rate by 2032 – DelveInsight | Key Companies – Merz Pharma, Proveca, NeuroHealing, Neos Pharma, Orient Pharma, US WorldMeds

 Breaking News
  • No posts were found

Sialorrhea Market is Projected to Boost at a Moderate Growth Rate by 2032 – DelveInsight | Key Companies – Merz Pharma, Proveca, NeuroHealing, Neos Pharma, Orient Pharma, US WorldMeds

August 10
00:21 2022
Sialorrhea Market is Projected to Boost at a Moderate Growth Rate by 2032 - DelveInsight | Key Companies - Merz Pharma, Proveca, NeuroHealing, Neos Pharma, Orient Pharma, US WorldMeds
Delveinsight Business Research LLP
According to DelveInsight, the Sialorrhea therapeutic market size in the seven major markets was USD 1073.62 Million in 2017 and is expected to increase during the forecast period (2032). Among the 7MM, the United States accounts for the largest market size for Sialorrhea in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

DelveInsight’s “Sialorrhea Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Sialorrhea Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Sialorrhea market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Sialorrhea: An Overview

Sialorrhea, also known as ptyalis, is the condition of excessive drooling in children with cerebral palsy and adults who suffers from neurodegenerative disorders. Drooling is of two types, anterior and posterior drooling. Anterior drooling is defined as saliva spilled from the mouth that is clearly visible. When saliva spills through the oropharynx and into the hypopharynx, it is known as posterior drooling.

Drooling saliva is normal in infants but usually stops by 15 to 18 months of age. Past the age of 4 years, it is usually considered to be pathologic. Pathologic sialorrhea is a common problem in neurologically impaired children (i.e., those with mental retardation or cerebral palsy) and adults with Parkinson’s disease or a stroke.

Sialorrhea Market Key Facts

  • In 2017, there were 2,484,780 cases of Sialorrhea in 7MM, among which the United States accounted for the most prevalent cases, with 1,132,426 cases in 2017.

  • Among the five major European Markets (EU5), the total number of prevalent cases of Sialorrhea were 999,549 in 2017, with the highest prevalent cases observed in Germany. Spain accounted for the least prevalent population of Sialorrhea, with 180,184 cases in 2017.

  • In Japan, the cases of PD-induced Sialorrhea were observed to be highest; however, multiple sclerosis induced Sialorrhea accounted for the least number of cases in Japan.

Sialorrhea Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Sialorrhea market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report details the Sialorrhea market trend for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.

Sialorrhea Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.

Sialorrhea Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Sialorrhea market or expected to get launched during the study period. The analysis covers Sialorrhea market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Sialorrhea Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report –  https://www.delveinsight.com/sample-request/sialorrhea-market

Sialorrhea Therapeutics Analysis

Currently, the treatment market for Sialorrhea comprises both prescribed and off-label medication. But, due to the expected launch of drugs in the later stage of development, the treatment market is anticipated to shift towards the approved medication.

Some of the key Companies in the Sialorrhea Market include:

  • Merz Pharmaceuticals

  • Proveca Pharma Ltd

  • US WorldMeds

  • NeuroHealing

  • Neos pharma

  • Orient pharma

And many others. 

Sialorrhea Therapies covered in the report include:

  • Myobloc

  • Xeomin (incobotulinumtoxinA)

  • NH004

  • Cuvposa

  • Sialanar (glycopyrronium bromide)

And many more.

Get More Detailed Insights Into the Emerging Therapies & Key Companies –  https://www.delveinsight.com/sample-request/sialorrhea-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Sialorrhea Competitive Intelligence Analysis

4. Sialorrhea Market Overview at a Glance

5. Sialorrhea Disease Background and Overview

6. Sialorrhea Patient Journey

7. Sialorrhea Epidemiology and Patient Population

8. Sialorrhea Treatment Algorithm, Current Treatment, and Medical Practices

9. Sialorrhea Unmet Needs

10. Key Endpoints of Sialorrhea Treatment

11. Sialorrhea Marketed Products

12. Sialorrhea Emerging Therapies

13. Sialorrhea Seven Major Market Analysis

14. Attribute Analysis

15. Sialorrhea Market Outlook (7 major markets)

16. Sialorrhea Access and Reimbursement Overview

17. KOL Views on the Sialorrhea Market.

18. Sialorrhea Market Drivers

19. Sialorrhea Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report – https://www.delveinsight.com/sample-request/sialorrhea-market

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

 

Other Trending Healthcare Reports by DelveInsight

Congestive Heart Failure (CHF) Market
“Congestive Heart Failure (CHF) Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Congestive Heart Failure Market size, share, and trends in the 7MM. Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics Market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/